Linked Life Data

20037303

Source:http://linkedlifedata.com/resource/pubmed/id/20037303

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-12-28
pubmed:abstractText
Concurrent chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is the standard treatment for unresectable locally advanced esophageal carcinoma. Although this regimen has been widely accepted in Japan, the adverse effect of CDDP such as gastrointestinal and renal toxicity may sometimes be the cause of interruption of the treatment, especially among the elderly patients. Cis-diammine-glycolatoplatinum(nedaplatin: CDGP) is a new platinum agent, which was developed with the aim of decreasing renal and gastrointestinal toxicities but maintaining the effectiveness of CDDP. We reported the efficacy and safety of CRT using CDGP and 5-FU for locally advanced squamous cell carcinoma of the esopahagus.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1997-9
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
pubmed:affiliation
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, and Department of Digestive Surgery, Osaka City General Hospital.
pubmed:publicationType
Journal Article, English Abstract